https://www.reuters.com/technology/exclusive-eu-mulls-new-unit-with-antitrust-veterans-enforce-tech-rules-sources-2022-07-28/
What’s Going On With Ovid Therapeutics After Takeda’s Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.